Noprex (Buprenorphine)

Buprenorphine acts as a partial agonist at the µ‑opioid receptor, delivering analgesia while limiting the ceiling effect for respiratory depression. It also antagonizes the κ‑opioid receptor, which may reduce dysphoria. The patch allows steady drug absorption through the skin, maintaining consistent plasma concentrations.

The prescribed dose of Noprex is determined by the treating clinician based on the patient’s pain severity, prior opioid exposure, and individual response. The prescriber selects the appropriate patch strength and duration according to clinical guidelines and patient needs.

Buprenorphine should be used in pregnancy or while breastfeeding only if the potential benefit justifies the possible risk to the fetus or infant. Clinicians must evaluate each case carefully and discuss potential risks and alternatives with the patient.

To request Noprex, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Compared with full opioid agonists, buprenorphine’s partial µ‑receptor agonism offers effective analgesia with a lower ceiling for respiratory depression and reduced risk of severe dependence. Its long‑acting transdermal delivery also provides more stable plasma levels than many oral or injectable opioids.

Noprex patches should be stored at room temperature, below 25 °C, in their original packaging. Keep them away from moisture, direct sunlight, and heat sources. Do not expose the patch to temperatures above the recommended range, as this may affect drug stability.

Noprex is applied to clean, dry, hair‑free skin on the upper back, chest, or upper arm. The patch adheres for the prescribed duration (typically 7 days). After removal, the site should be inspected for irritation, and a new patch applied to a different area.

Serious risks include respiratory depression, severe hypotension, opioid dependence, and rare allergic reactions such as anaphylaxis. Patients should be monitored for signs of excessive sedation, shallow breathing, or any unexpected adverse events, especially during dose initiation or changes.

Noprex is contraindicated in individuals with known hypersensitivity to buprenorphine, the patch’s adhesive components, or any of its excipients. It should also be avoided in patients with severe respiratory compromise, acute severe asthma, or those taking prohibited concomitant medications without appropriate medical supervision.